Welcome to our dedicated page for Cbdmd news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on Cbdmd stock.
cbdMD, Inc. (NYSE American: YCBD) generates a steady flow of corporate, financial, and strategic news tied to its position in the hemp-derived wellness and cannabinoid products space. Company press releases and SEC filings highlight developments across its cbdMD and Paw CBD brands, ATRx Labs functional mushroom products, and Herbal Oasis hemp-derived THC social seltzers, as well as capital markets activity and exchange-listing matters.
News for YCBD often covers operating performance, including updates on net sales, gross profit, and operating loss trends disclosed in conjunction with annual and quarterly results. The company has reported multiple years of operating improvement and has discussed cost management, product portfolio optimization, and marketing investments in its communications. Investors following YCBD news also see disclosures about preferred stock financings, such as Series B and Series C Convertible Preferred Stock, and the establishment of an equity line of credit registered on Form S-1.
Regulatory and listing-related announcements form another key part of cbdMD’s news flow. The company has reported regaining full compliance with NYSE American continued listing standards after addressing equity-related deficiencies, and it has furnished related information through Form 8-K filings. Policy commentary around federal discussions on cannabinoids and hemp-derived products, and how those discussions may affect research and investment in the category, also appears in its releases.
Strategic updates, including the asset acquisition of Gaia Botanicals, LLC and its Bluebird Botanicals brand and online CBD marketplace, are disclosed through press releases and 8-K filings. These items provide detail on how cbdMD is expanding its brand portfolio, intellectual property base, and product offerings in CBD and related categories. For investors and observers, the YCBD news page offers a centralized view of earnings communications, capital transactions, regulatory milestones, and brand-level initiatives across cbdMD’s wellness platform.
cbdMD, Inc. (NYSE American: YCBD) has announced the launch of its new full spectrum product line, which includes tinctures and softgels with trace THC levels compliant with the 2018 Farm Bill. This expansion marks a significant milestone for the company, as full spectrum products account for over 50% of the total CBD market, according to the Brightfield Group. The introduction of these new offerings aims to broaden cbdMD's customer base while maintaining its commitment to THC-free options. Current available products can be found on cbdMD.com.
cbdMD, Inc. (NYSE American: YCBD) has partnered with four top CrossFit athletes, including 2021 champion Justin Medeiros and two-time champion Annie Thorisdottir, to enhance its presence in the fitness sector. This announcement follows their role as the Official CBD Partner of the 2021 NOBULL CrossFit Games. The partnerships aim to reach over three million Instagram followers and increase product awareness within the CrossFit community, which comprises around four million members globally.
cbdMD, Inc. (NYSE American: YCBD) has launched a full line of CBD drink mixes, available in four flavors: Strawberry Kiwi, Lemonade, Peach, and Fruit Punch. Each packet contains 25 mg of CBD and added vitamin C, utilizing Nano-Encapsulated Technology for rapid absorption. The new products aim to simplify CBD consumption for busy lifestyles and are designed for on-the-go use. The company anticipates introducing more innovative products this Fall, indicating a commitment to product diversification and customer convenience.
cbdMD reported third-quarter results for fiscal 2021 with net sales of $10.6 million, steady year-over-year, marking record trailing twelve-month net sales over $46.4 million.
Gross profit margin improved to approximately 68%, up from 65% a year earlier. Despite a 4.9% decline in e-commerce sales, wholesale sales increased by 13.7%.
Operating expenses surged 40.6% to $13.9 million, resulting in a loss from operations of $6.7 million. The company adjusted its net sales guidance for Q1 fiscal 2022, estimating $14.9 million to $15.5 million.
cbdMD, Inc. (NYSE American: YCBD) has signed a binding letter of intent with IM Cannabis Corp. (CSE: IMCC) for the exclusive rights to import and market its products in Israel, pending legislative approval. The collaboration aims to tap into the projected $475 million Israeli CBD market by 2025. This partnership reflects cbdMD's commitment to expanding its international presence, with operations in over 30 countries. CEO Martin Sumichrast emphasized the potential to leverage IMC's distribution capabilities to reach new consumers.
cbdMD, Inc. (NYSE American: YCBD) announced a conference call to discuss its financial results for the third quarter ended June 30, 2021. The call is scheduled for August 12, 2021, at 4:15 p.m. ET. Interested parties can join via domestic at 1-888-506-0062 or international at 1-973-528-0011. A replay will be available until August 12, 2022, using the passcode 42434. The company highlights its extensive portfolio of THC-free CBD products, including over 130 SKUs across various categories.
cbdMD, Inc. (NYSE American: YCBD) has signed a letter of intent to acquire DirectCBDOnline.com from Twenty Two Capital, LLC. This acquisition aims to enhance cbdMD's direct-to-consumer e-commerce capabilities and gain insights into consumer trends within the CBD market. John Wiesehan III, co-founder of DirectCBDOnline.com, will be appointed as Chief Revenue Officer post-acquisition. The transaction is expected to finalize by July 31, 2021, but is subject to customary closing conditions which could affect completion.
cbdMD, Inc. (NYSE American: YCBD) announced that its cbdMD Therapeutics division is in discussions with a prominent US cannabinoid research institute to explore novel cannabinoids for therapeutic use. The company plans to finalize an agreement and start studies by Fall 2021, focusing on data for its research pipeline. The research aims to support clinical trials and potential FDA applications, which could enable cbdMD to make scientifically backed claims for its products. This initiative is expected to boost brand reputation and expand distribution opportunities across various channels.
cbdMD, Inc. (NYSE American: YCBD) has successfully closed its public offering, raising $16.5 million in gross proceeds. The company sold 2,200,000 shares of its 8.0% Series A Cumulative Convertible Preferred Stock at a price of $7.50 per share, including an over-allotment option of 286,900 shares. The net proceeds are intended for working capital. ThinkEquity served as the underwriter for this offering.
cbdMD, Inc. (NYSE American: YCBD, YCBDpA) has priced its public offering of 1,913,100 shares of 8.0% Series A Cumulative Convertible Preferred Stock at $7.50 each, aiming to raise gross proceeds of $14,348,250. Closing is expected around July 1, 2021, pending customary conditions. Shares are convertible at $6.00 per share unless certain trading conditions are met. The company plans to use net proceeds for working capital and general corporate purposes. ThinkEquity is the book-running manager for this offering.